Genetics of Covid-19 patients is focus of study
Research into the genetic code of Covid-19 patients could help predict severity of the disease.
Researchers are to study the genetic blueprints of severely ill Covid-19 patients to find out why the disease affects some more seriously than others and suggest potential treatments.
A UK-wide initiative will sequence the genetic makeup – the whole genome – of patients to identify the specific genes that cause a predisposition to the disease.
The study hopes to explain one of the biggest mysteries about Covid-19: why some people get no symptoms at all, while others become critically ill, or die.
The project, led by Dr Kenneth Baillie from the Roslin Institute, is a collaboration between Genomics England, the NHS, and the GenOMICC (Genetics of Susceptibility and Mortality in Critical Care) consortium – a global consortium to study genetics in critical illness.
This new partnership will allow whole genome sequencing to take place across the NHS involving up to 20,000 people currently or previously in an intensive care unit with Covid-19, and 15,000 individuals who have mild symptoms.
All critically ill patients
GenOMICC – which was launched by Dr Baillie in 2016 - is already active in more than 170 intensive care units across the UK and has signed up more than one thousand patients for the study.
The team aim to recruit every Covid-19 patient on a ventilator in the UK. The group have now been funded to sequence the entire genomes of patients with Covid-19 in collaboration with Genomics England and Illumina.
By discovering why some people are predisposed to developing life-threatening symptoms, scientists will be able to identify treatments for clinical trials and potentially highlight people at extreme risk.
The results will also inform global strategic planning for possible later waves of Covid-19 and for future pandemics.
GenOMICC is an open, global consortium of intensive care clinicians to understand genetic factors that influence outcomes in intensive care from diseases such as SARS, influenza and sepsis. It is designed to enable rapid research in the event of outbreaks like the current pandemic.
It is funded by the charity Sepsis Research (FEAT), the Intensive Care Society, Wellcome, UKRI and Scotland’s Chief Scientist Office.
This new work has been enabled by £28 million of funding from Genomics England, UK Research and Innovation, the Department of Health and Social Care and the National Institute for Health Research.
I am delighted to be announcing this further major programme in the UK’s fight against Covid-19. As a nation, we are determined to harness the UK’s leadership in genomics to understand its role in viral response and whether we can use this information to identify those at greatest risk and improve their treatment.
Our genes play a role in determining who becomes desperately sick with infections like Covid-19. Understanding these genes will help us to choose treatments for clinical trials. The GenOMICC study was launched before this outbreak and it is recruiting in 145 ICUs across the country with tremendous support from the critical care community. We are excited to work with Genomics England to tackle this new and complex disease.
For the first time in a generation, we face a global viral pandemic that is life threatening for some people, yet others have a mild infection. By reading the whole genome we may able to identify variation that affects response to Covid-19 and discover new therapies that could reduce harm, save lives and even prevent future outbreaks.
** The Roslin Institute receives strategic investment funding from the Biotechnology and Biological Sciences Research Council and it is part of the University of Edinburgh’s Royal (Dick) School of Veterinary Studies. **
Edd McCracken, Press and PR Office, University of Edinburgh
Obesity impacts on Covid-19 recovery prospect
£5m Covid-19 study seeks to understand virus impact
Roslin broadens research tackling Covid-19